



Aspira Pathlab & Diagnostics Limited

(Formerly known as Utkal Soap Products Ltd.)

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN:L85100MH1973PLC289209

Corporate Office: Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703

January 21, 2019

BSE Limited

The Corporate Relationship Department
P.J. Towers,
Dalal Street,
Mumbai - 400001

Scrip Code: 540788

Dear Sir/ Madam,

Sub: Outcome of meeting of the Board of Directors of Aspira Pathlab & Diagnostics Limited

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (read with Part A of schedule III), We hereby inform you that the Board of Directors of the Company, at its meeting held today i.e. Monday, January 21, 2019 inter alia considered and approved the unaudited Standalone financial results of the Company for the quarter and nine months ended December 31, 2018 and the same are enclosed herewith along with Limited Review Reports given by the Statutory Auditors on the above financial results.

The meeting of the Board of Directors commenced at 3.15 pm and concluded at 5:45 pm.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For **ASPIRA PATHLAB & DIAGNOSTIC LIMITED**

M. Mav

Mamta Mav

Company Secretary



Aspira Pathlab & Diagnostics Limited

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Statement of Unaudited Financial Results for the Quarter ended and Nine Months ended 31st December, 2018

(Rs. in Lakhs)

Particulars	Quarter ended			Nine Months		Year ended
	31-Dec-18 (Unaudited)	30-Sep-18 (Unaudited)	31-Dec-17 (Unaudited)	31-Dec-18 (Unaudited)	31-Dec-17 (Unaudited)	31-Mar-18 (Audited)
1. Income						
(a) Revenue from Operations						
Sales/Income from Operations	208.06	199.78	126.15	556.01	288.50	435.78
Other Operating Income						-
(b) Other Income	7.18	5.57	4.36	17.79	15.22	22.05
Total income	215.24	205.35	130.51	573.80	303.72	457.83
2. Expenses						
(a) Cost of Materials consumed	72.66	36.03	26.97	153.87	75.73	130.18
(b) Purchase of stock-in-trade		-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-	-	-	-	-
(d) Employee benefits expense	115.28	109.25	90.95	328.25	244.07	342.38
(e) Finance Costs	16.14	26.18	17.76	70.50	51.69	80.48
(f) Depreciation and amortisation expense	31.00	30.68	39.97	91.16	99.49	112.46
(g) Other expenses	103.40	136.12	89.23	323.92	253.91	350.56
Total Expenses	338.48	338.26	264.88	967.70	724.89	1,016.06
3. Profit / (Loss) before exceptional items and tax (1-2)	(123.24)	(132.91)	(134.37)	(393.90)	(421.17)	(558.23)
4. Exceptional Items		-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	(123.24)	(132.91)	(134.37)	(393.90)	(421.17)	(558.23)
6. Tax Expenses		-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	(123.24)	(132.91)	(134.37)	(393.90)	(421.17)	(558.23)
8. Other Comprehensive income (net of tax)		-	-	-	-	-
9. Total Comprehensive income (7+8)	(123.24)	(132.91)	(134.37)	(393.90)	(421.17)	(558.23)
10. Paid up Equity share capital (face value 10 each)	819.30	819.30	519.30	819.30	519.30	519.30
11. Earning per share						
(a) Basic	(1.50)	(1.62)	(2.59)	(4.81)	(8.11)	(10.75)
(b) Diluted	(1.50)	(2.08)	(2.59)	(4.10)	(8.11)	(10.75)

Notes

- The previous period figures have been regrouped wherever necessary.
- The above result of the company have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 21st January 2019. The Statutory auditors of the Company have carried out a limited review of above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- The unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Balkrishna S. Talawadekar
Chief Financial Officer



Place : Mumbai
Date : 21.01.2019



P KHETAN & CO
Chartered Accountants

19B B BGanguly Street
Room No. 5, 2nd Floor
Kolkata – 700012
Phone- 033-40734009
Mobile- 9883093350
e-mail- khetanpk@gmail.com

Limited Review Report for the quarter/nine months ended on 31st December 2018

The Board of Directors

AspiraPathlab & Diagnostics Limited

(Formerly known as Utkal Soap Products Limited)

Flat No.2, R.D. Shah Bldg,

Shraddhanand Road Opp. Ghatkopar Railway Station,

Ghatkopar (West)

Mumbai – 400086


We have reviewed the accompanying statement of **Unaudited Standalone Financial Results of Aspira Pathlab & Diagnostics Limited (Formerly known as Utkal Soap Products Limited)** for the quarter and nine months ended December 31, 2018 (“the Statement”) being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 .

This statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Khetan & Co
Chartered Accountant


(Pankaj Kumar Khetan)
Partner

M.No- 066080

Firm Reg. No- 327386E

Date- 21.01.2019

